Back to results
US 2022/0175718 A1Published application
Transdermal pharmaceutical formulations for the treatment of cancer
AssigneePike Therapeutics Inc.
InventorsFotios M. Plakogiannis, Tamanna Lather, Nisarg Modi, Marina Borovinskaya
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating cancer and, more particularly, an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, in a dosage form for transdermal delivery in the treatment of cancer.
Claims74
A pharmaceutical composition comprising at least one active agent selected from the group consisting of:
- about 3% to about 15% of an active agent selected from the group consisting of cannabidiol (CBD), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof;
- about 3% to about 15% of an active agent selected from the group consisting of tetrahydrocannabinol (THC), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof;
- and
- combinations thereof,
- further wherein the pharmaceutical composition comprises:
- about 0% to about 97% of at least one solvent;
- about 0% to about 97% of at least surfactant;
- optionally, about 0% to about 97% of at least one permeation enhancer;
- and/or
- optionally, about 0% to about 97% of an adhesive and/or polymer.
7 more elements
A method for the treatment and/or prevention and/or control of cancer in a patient comprising:
- selecting a patient in need of treatment and/or prevention and/or control of cancer;
- applying a pharmaceutical composition comprising at least one active agent selected from the group consisting of:
- about 3% to about 15% of an active agent selected from the group consisting of cannabidiol (CBD), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof;
- about 3% to about 15% of an active agent selected from the group consisting of tetrahydrocannabinol (THC), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof;
- and
- combinations thereof,
- further wherein the pharmaceutical composition comprises:
- about 0% to about 97% of at least one solvent;
- about 0% to about 97% of at least surfactant;
- optionally, about 0% to about 97% of at least one permeation enhancer;
- and/or
- optionally, about 0% to about 97% of an adhesive and/or polymer,
- thereby treating and/or preventing and/or controlling cancer in the patient.
10 more elements
Dependencies are inferred from the claim text.